Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double—Blind,Randomized Controlled Trial
Free accessResearch articleFirst published online July, 2013
Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double—Blind,Randomized Controlled Trial
To investigate whether long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs) improve functioning and psychiatric symptoms in young people with borderline personality disorder (BPD) who also meet ultra-high risk criteria for psychosis.
Methods:
We conducted a post hoc subgroup analysis of a double-blind, randomized controlled trial. Fifteen adolescents with BPD (mean age 16.2 years, [SD 2.1]) were randomized to either 1.2 g/day n-3 PUFAs or placebo. The intervention period was 12 weeks. Study measures included the Positive and Negative Syndrome Scale, the Montgomery–Åsberg Depression Rating Scale, and the Global Assessment of Functioning. Side effects were documented with the Udvalg for Kliniske Undersøgelser. Fatty acids in erythrocytes were analyzed using capillary gas chromatography.
Results:
At baseline, erythrocyte n-3 PUFA levels correlated positively with psychosocial functioning and negatively with psychopathology. By the end of the intervention, n-3 PUFAs significantly improved functioning and reduced psychiatric symptoms, compared with placebo. Side effects did not differ between the treatment groups.
Conclusions:
Long-chain n-3 PUFAs should be further explored as a viable treatment strategy with minimal associated risk in young people with BPD.
American Psychiatric Association (APA)Diagnostic and statistical manual of mental disorders. 4th ed.Washington (DC): APA; 1994.
2.
TrullTJJahngSTomkoRLRevised NESARC personality disorder diagnoses: Gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412–426.
3.
ZimmermanMChelminskiIYoungD.The frequency of personality disorders in psychiatric patients. Psychiatr Clin North Am. 2008;31(3):405–420.
4.
TackettJLBalsisSOltmannsTFA unifying perspective on personality pathology across the life span: Developmental considerations for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. Dev Psychopathol. 2009;21(3):687–713.
5.
JohnsonJGCohenPKasenSAge-related change in personality disorder trait levels between early adolescence and adulthood: A community-based longitudinal investigation. Acta Psychiatr Scand. 2000;102(4):265–275.
6.
SamuelsJEatonWWBienvenuOPrevalence and correlates of personality disorders in a community sample. Br J Psychiatry. 2002;180(6):536–542.
7.
UllrichSCoidJ.The age distribution of self-reported personality disorder traits in a household population. J Pers Disord. 2009;23(2):187–200.
8.
ChanenAMJovevMMcCutcheonLBorderline personality disorder in young people and the prospects for prevention and early intervention. Curr Psychiatry Rev. 2008;4(1):48–57.
9.
MillerALMuehlenkampJJJacobsonCM. Fact or fiction: Diagnosing borderline personality disorder in adolescents. Clin Psychol Rev. 2008;28(6):969–981.
10.
SkodolAE. Scientific issues in the revision of personality disorders for DSM-5. Pers Ment Health. 2011;5(2):97–111.
11.
GundersonJGStoutRLMcGlashanTHTen-year course of borderline personality disorder: Psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry. 2011;68(8):827–837.
ChanenAMJacksonHJMcCutcheonLKEarly intervention for adolescents with borderline personality disorder using cognitive analytic therapy: Randomised controlled trial. Br J Psychiatry. 2008;193(6):477–484.
14.
LiebKVollmBRuckerGPharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. Br J Psychiatry. 2010;196:4–12.
15.
TsapakisEMSoldaniFTondoLEfficacy of antidepressants in juvenile depression: Meta-analysis. Br J Psychiatry. 2010;193:10–17.
16.
IngenhovenTJMDuivenvoordenHJ. Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31(4):489–496.
17.
ParisJ.Pharmacological treatments for personality disorders. Int Rev Psychiatry. 2011;23(3):303–309.
18.
GeschCBHammondSMHampsonSEInfluence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomized, placebo-controlled trial. Br J Psychiatry. 2002;181:22–28.
19.
GarlandMRHallahanBMcNamaraMLipids and essential fatty acids in patients presenting with self-harm. Br J Psychiatry. 2007;190:112–117.
20.
HallahanBHibbelnJRDavisJMOmega-3 fatty acid supplementation in patients with recurrent self-harm. Singlecentre double-blind randomised controlled trial. Br J Psychiatry. 2007;190:118–122.
21.
ZanariniMCFrankenburgFR. Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167–169.
22.
BarnowSArensEASieswerdaSBorderline personality disorder and psychosis: A review. Curr Psychiatry Rep. 2010;12(3):186–195.
SlotemaCWDaalmanKBlomJDAuditory verbal hallucinations in patients with borderline personality disorder are similar to those in schizophrenia. Psychol Med. 2012;16:1–6.
25.
GeorgeASoloffPH. Schizotypal symptoms in patients with borderline personality disorders. Am J Psychiatry. 1986;143(2):212–215.
26.
ThompsonANelsonBDominguesIBorderline personality features and transition to psychosis in an “ultra high risk” (UHR) population: A case–control study. Early Interv Psychiatry. 2012;6(3):247–255.
27.
FranceySMJovevMPhassouliotisCCo-morbid borderline personality disorder and first episode psychosis: How many and what happens? [Meeting abstract]. Schizophr Res. 2006;86:S113–S113.
28.
GleesonJFMChanenAMCottonSMTreating co-occurring first-episode psychosis and borderline personality: A pilot randomized controlled trial. Early Interv Psychiatry. 2012;6(1):21–29.
29.
AmmingerGPSchäferMRPapageorgiouKLong-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146–154.
30.
YungARPhillipsLJMcGorryPDPrediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172:14–20.
31.
KaySRFiszbeinAOplerLA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
32.
MorrisonAPFrenchPWalfordLCognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. Br J Psychiatry. 2004;185:291–297.
33.
AndreasenNCEndicottJSpitzerRLThe family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry. 1977;34(10):1229–1235.
34.
MontgomerySAAsbergM.A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
35.
LingjaerdeOAhlforsUGBechPThe UKU side effect rating scale. Acta Psychiatr Scand. 1987;334:1–100.
36.
FreemanMPHibbelnJRWisnerKLOmega-3 fatty acids: Evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954–1967.
37.
GoodmanMNewASTriebwasserJPhenotype, endophenotype, and genotype comparisons between borderline personality disorder and major depressive disorder. J Pers Disord. 2010;24(1):38–59.
38.
SubletteMERussMJSmithGS. Evidence for a role of the arachidonic acid cascade in affective disorders: A review. Bipolar Disord. 2010;6:95–105.
39.
ZanariniMCStanleyBBlackDWMethodological considerations for treatment trials for persons with borderline personality disorder. Ann Clin Psychiatry. 2010;22(2):75–83.
40.
AppletonKMRogersPJNessAR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757–770.
41.
SubletteMEEllisSPGeantALMeta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577–1584.
